Overcoming the epidemic, Longyao Bio's Phase I clinical trial for relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma successfully completed the first subject reinfusion in Shanghai Ruijin Hospital
Recently, the raging of the new crown epidemic has caused a lot of inconvenience to the society.
- · Longyao Bio completed the first patient enrollment in Phase I clinical trials for relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma2022-03-04
- · News: Progress of a Phase I clinical program (LY011 program) to evaluate the treatment of advanced malignant solid tumors2022-02-17
- · The chief scientist of Longyao Bio was invited to attend the 2021 Biopharmaceutical Innovation Technology Conference2021-08-12
Immune cell technology
Genetic engineering technology
Stem Cell Technology
Tissue Engineering Technology
Shanghai Longyao Biotechnology Co., Ltd. was established in 2013 and is located in Jing'an District, Shanghai. It is committed to tumor immune cell technology and product research and development, product technology transformation, and product registration application. It is a national high-tech enterprise focusing on research and development and product development. Products cover hematological tumors, solid tumors and other fields.